Meprobamate
was introduced as an anti-anxiety agent in 1955
and is prescribed primarily to treat anxiety,
tension, and associated muscle spasms. More than
50 tons are distributed annually in the United
States under its generic name and brand names
such as Miltown® and Equanil®. Its onset
and duration of action are similar to the intermediate-acting
barbiturates; however, therapeutic doses of meprobamate
produce less sedation and toxicity than barbiturates.
Excessive use can result in psychological and
physical dependence. Carisoprodol (Soma®),
a skeletal muscle relaxant, is metabolized to
meprobamate. This conversion may account for some
of the properties associated with carisoprodol
and likely contributes to its abuse.
Source: DEA |
